[Possibilities of non-hormonal drug treatment of osteoporosis].
In many countries osteoporosis is the most common metabolic bone diseases. A great deal is known about the pathophysiology and the treatment of the disease. There is a lot of treatment possibilities and many new treatments are being tested. Therapeutic agents for osteoporosis are correspondingly classified as substances primarily inhibiting bone turnover (most of them are inhibitors of bone resorption as well) and agents that appear capable of restoring bone mass previously lost (stimulators of bone formation). From a didactic point of view the distinction of these to groups is generally accepted, but pharmacologically there is a considerable overlap between two. In this review the authors evaluate non-hormonal drugs, which are being used widely in the treatment of osteoporosis. The key points of the evaluation are the mechanism of action, the effects on bone mass, bone strength and fracture.
Szathmári
M
M
I. Belgyógyászati Klinika, Semmelweis Orvostudományi Egyetem, Budapest.
Châtel
R
R
D000328:Adult; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology; D001581:Benzothiadiazines; D002116:Calcitonin / Q000008:administration & dosage* / Q000494:pharmacology; D002118:Calcium / Q000008:administration & dosage* / Q000494:pharmacology; D004232:Diuretics; D005260:Female; D006801:Humans; D008593:Menopause / Q000502:physiology*; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control*; D017698:Postmenopause / Q000502:physiology*; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000494:pharmacology
D045930:Anabolic Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D002116:Calcitonin; D002118:Calcium